AACR22: As post-Covid development takes shape, BioNTech reports first human data for CAR-T/cancer vaccine combo

Continuing to push into new frontiers following the huge success of its Covid-19 vaccine, BioNTech revealed the first-in-human data for its combination CAR-T and mRNA cancer therapy.

In a Phase I portion of a Phase I/II study, the German biotech reported that six of 14 evaluable patients achieved a partial response six weeks after treatment, with one advancing to a complete response by Week 18. Four of the responses came in testicular cancer patients, while the other two manifested in individuals with ovarian cancer.